A LONG-TERM FOCUS
                      ON INNOVATION

                      We welcome the opportunity to discuss:

                      BUSINESS
                      DEVELOPMENT
                      COLLABORATIONS

                      • In-licensing and / or R&D collaborations
                        • Creative collaborations in emerging fields
                        • Best-in-class technology platforms and capabilities to enhance the Regeneron antibody pipeline
                      • Strategic late-stage development and commercial partnerships with other leading biopharma companies
                      • Collaborations that maximize the global potential of our pipeline and ability to deliver new medicines to patients around the globe

                      Introduce your assets or discuss
                      late-stage partnership

                      ACADEMIC &
                      RESEARCH
                      COLLABORATIONS

                      • Non-Clinical Research Collaborations providing investigators from academic and research institutions access to our:

                      Learn more

                      • Clinical Collaborations / Investigator Initiated Studies (IIS) providing investigators and clinicians access to and / or funding for our:

                      Learn more

                      OUR BUSINESS DEVELOPMENT STRATEGY

                      Our entrepreneurial culture and history as one of the industry’s longest-standing biotech companies fosters a high-science mindset, nimble decision-making and highly collaborative relationships.

                      We follow the science, rather than limiting our innovations to any one therapeutic area. We are open to collaboration opportunities with the potential to offer important benefits to patients, representing a true scientific or medical advance. In particular, we consider:

                      • Novel platforms that enable next-generation therapeutics
                      • Technologies for antibody discovery and development against new / challenging targets
                      • New approaches that enhance activity of tumor-directed antibodies
                      • Biomarker discovery and validation
                      • Drug delivery or formulation technologies that improve the efficacy / safety profile, address a CMC or supply challenge or enhance patient convenience or compliance
                      • Studying the potential of combinations pairing our pipeline molecules with other innovative clinical-stage therapeutic candidates
                      • Collaborations with leading academic groups to advance our efforts in human genetics, animal model development, target discovery, target validation and antibody discovery

                      SOME OF OUR CURRENT COLLABORATORS INCLUDE:


                      BAYER logo

                      Global ophthalmology
                      collaborations

                      SANOFI logo

                      Antibody and immunotherapy
                      collaborations

                      Icahn School of Medicine at Mount Sinai logo

                      Antibody discovery
                      agreement

                      Columbia University logo

                      Research collaboration on genetic
                      basis of familial disease

                      TEVA logo

                      Global collaboration for
                      investigational pain therapeutic

                      Intellia Therapeutics logo

                      Gene-editing technology
                      collaboration

                      Adicet Bio logo

                      Engineered immune cell
                      therapeutics collaboration

                      Alnylam Pharmaceuticals logo

                      RNA interference (RNAi)
                      therapeutics collaboration

                      国产一级毛片在线播放